Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01566539 · ClinicalTrials.gov registry record · NA
Biological Basis of Individual Variation in Social Cooperation
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 707
- Enrollment target
NCT01566539: Completed NA study, sponsored by Emory University.
NCT01566539 is a NA study that has completed, run by Emory University. The registered enrollment target is 707 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01566539, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 707 participants
- Enrollment target
Study Summary
The project has three overall objectives. The first is to determine whether and how administration of intranasal oxytocin (OT) and intranasal vasopressin (AVP) influence cooperative decision-making and neural responses to cooperative and un-cooperative social interactions. The second is to determine whether and how intranasal vasopressin influences subjective evaluations of and neural responses to same and opposite-sex face stimuli and to determine if any of these effects persist beyond the period of AVP exposure. The third objective is to determine if intranasal OT influences empathy-related behavior and associated brain activity.
Primary Outcome
The effect of the drug treatment will be assessed by determining differences in brain activation between OT and placebo groups in the right caudate nucleus region during reciprocated cooperation in Prisoner Dilemma game while undergoing an fMRI scan.
Interventions
- DRUG Lorazepam
- DRUG Intranasal Placebo
- DRUG Intranasal Oxytocin (OT) 24 IU
- DRUG Intranasal Vasopressin (AVP)
- DRUG Intranasal Vasopressin (AVP) 40 IU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 707 participants |
| Start Date | 2008-04 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT01566539 record still lists
NCT01566539 is an interventional study that assigns participants to a tested intervention. The registered 707 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 5 interventions - of which Lorazepam is the first listed.
NCT01566539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01566539 about?
NCT01566539 is a clinical study titled "Biological Basis of Individual Variation in Social Cooperation". The project has three overall objectives. The first is to determine whether and how administration of intranasal oxytocin (OT) and intranasal vasopressin (AVP) influence cooperative decision-making and neural responses to cooperative and un-cooperative social interactions. The second is to determine...
What is the current status of trial NCT01566539?
This trial is currently completed. It is a NA study. The enrollment target is 707 participants. The study started on 2008-04. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01566539?
The interventions under investigation include: Lorazepam (DRUG), Intranasal Placebo (DRUG), Intranasal Oxytocin (OT) 24 IU (DRUG), Intranasal Vasopressin (AVP) (DRUG), Intranasal Vasopressin (AVP) 40 IU (DRUG).
Who is sponsoring clinical trial NCT01566539?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01566539's enrollment target sits among peer trials
707 148th of 2000 higher than 1,853 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia